Dupont Capital Management Corp acquired a new position in shares of Genomic Health, Inc. (NASDAQ:GHDX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 32,253 shares of the medical research company’s stock, valued at approximately $1,103,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GHDX. Bank of New York Mellon Corp raised its stake in Genomic Health by 1.3% during the second quarter. Bank of New York Mellon Corp now owns 89,714 shares of the medical research company’s stock worth $2,921,000 after acquiring an additional 1,137 shares during the period. Legal & General Group Plc raised its stake in Genomic Health by 11.4% during the second quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock worth $226,000 after acquiring an additional 710 shares during the period. Swiss National Bank grew its position in Genomic Health by 8.7% in the 2nd quarter. Swiss National Bank now owns 33,900 shares of the medical research company’s stock worth $1,103,000 after purchasing an additional 2,700 shares during the last quarter. Wells Fargo & Company MN grew its position in Genomic Health by 18.2% in the 2nd quarter. Wells Fargo & Company MN now owns 61,075 shares of the medical research company’s stock worth $1,987,000 after purchasing an additional 9,391 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in Genomic Health by 10.6% in the 2nd quarter. Teachers Advisors LLC now owns 35,177 shares of the medical research company’s stock worth $1,145,000 after purchasing an additional 3,376 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Genomic Health, Inc. (NASDAQ:GHDX) opened at $33.66 on Thursday. Genomic Health, Inc. has a 1 year low of $26.54 and a 1 year high of $37.50.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Wednesday, November 8th. The medical research company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.04. The firm had revenue of $83.82 million during the quarter, compared to analysts’ expectations of $87.06 million. Genomic Health had a negative net margin of 1.30% and a negative return on equity of 1.79%. equities research analysts predict that Genomic Health, Inc. will post -0.09 earnings per share for the current fiscal year.

Several research analysts have commented on GHDX shares. Zacks Investment Research upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. Jefferies Group restated a “hold” rating and issued a $34.00 target price on shares of Genomic Health in a research report on Friday, October 20th. ValuEngine cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Canaccord Genuity restated a “buy” rating and issued a $39.00 target price on shares of Genomic Health in a research report on Wednesday, November 15th. Finally, JPMorgan Chase & Co. cut shares of Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 target price for the company. in a research report on Wednesday, December 13th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $32.33.

In other news, insider Laura Leber sold 21,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $33.29, for a total value of $699,090.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $29.94, for a total transaction of $149,700.00. The disclosure for this sale can be found here. Insiders sold 69,338 shares of company stock valued at $2,305,951 over the last quarter. Insiders own 46.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Dupont Capital Management Corp Invests $1.10 Million in Genomic Health, Inc. (GHDX) Stock” was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/02/08/dupont-capital-management-corp-invests-1-10-million-in-genomic-health-inc-ghdx-stock.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.